Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance

/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2022, raised 2022 financial guidance and...

Related Keywords

Ireland ,France ,Germany ,Norway ,Japan ,United Kingdom ,Italy ,Dublin ,Spain ,Switzerland ,Sumitomo Pharma ,Kristin Bhavnani ,Andrean Flynn ,Redx Pharma ,Erwinaze Erwinase ,Oxybate Xywav ,Rob Iannone ,Epidiolex Epidyolex ,Bruce Cozadd ,Jazz Pharmaceuticals To Sumitomo Pharma ,Roche Ltd ,Jazz Pharmaceuticals ,Drug Administration ,Head Of Global Corporate Communications ,Nasdaq ,Gw Pharmaceuticals ,Company Annual Report On Form ,Exchange Commission ,Prnewswire Jazz Pharmaceuticals ,Corporate Development ,Sumitomo Pharma Co Ltd ,Rylaze Supplemental Biologics License Application ,Real Time Oncology Review ,Orphan Drug Exclusivity ,Idiopathic Hypersomnia ,Myoclonic Atonic Seizures ,Orange Book ,Werewolf Therapeutics ,Investigational New Drug ,Strategic Divestiture ,New Drug Application ,Fast Track Designation ,American Association ,Cancer Research Annual Meeting ,Own Equity ,Convertible Instruments ,Exchangeable Senior ,Effective Tax ,Euro Term Loan ,Exchangeable Senior Notes ,Jazz Pharmaceutical ,Adjusted Consolidated ,Jazz Pharmaceutical Securities ,Annual Report ,Certain Line Items ,Net Debt ,Pro Forma ,Leverage Ratio ,Consolidated Adjusted ,Global Corporate ,Jazz Pharmaceuticals Plc ,